<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690051</url>
  </required_header>
  <id_info>
    <org_study_id>FMRP-140702</org_study_id>
    <nct_id>NCT02690051</nct_id>
  </id_info>
  <brief_title>BeSmooth Study, Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions</brief_title>
  <acronym>BeSmooth</acronym>
  <official_title>BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flanders Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flanders Medical Research Program</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Physician initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the&#xD;
      treatment of Iliac Lesions.&#xD;
&#xD;
      The objective of this clinical investigation is to evaluate the long-term safety and efficacy&#xD;
      of the BeSmooth Peripheral Stent System in clinical settings post CE-certification when used&#xD;
      according to the indications of the IFU.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.4) and without Target Lesion Revascularization (TLR) within 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency at 1 &amp; 6 month</measure>
    <time_frame>1 and 6 months</time_frame>
    <description>Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.4) and without prior TLR are defined as being primary patent at the given follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Occlusion Rate at 1,6 and 12-month follow-up</measure>
    <time_frame>up to 12 months</time_frame>
    <description>100% (re)occlusion rate within the study stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI at 1,6 and 12-month follow-up, compared with baseline</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Ankle-Brachial index measurements at 1,6 and 12-month FU visit, compared with measurements at baseline (pre operatively)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate at 1,6 and 12-month follow-up</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance success rate at baseline, defined as restoration of blood flow</measure>
    <time_frame>during the index study procedure</time_frame>
    <description>Device success, restoration of blood flow during index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent restenosis rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>restenosis rate within the study stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Target Lesion Revascularization</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Freedom from Target Lesion Revascularization (TLR), defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serious Adverse Events (SAEs), defined according to ISO 14155:2011 as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>during the index study procedure</time_frame>
    <description>The ability to achieve final residual angiographic stenosis no greater than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success at follow-up is defined as an improvement of Rutherford Classification at 1-,6- and 12-month follow-up</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Clinical success at follow-up is defined as an improvement of Rutherford classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>BeSmooth Peripheral Stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with the BeSmooth Peripheral Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BeSmooth peripheral stent</intervention_name>
    <description>patients treated with the BeSmooth Peripheral Stent System</description>
    <arm_group_label>BeSmooth Peripheral Stent system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Corresponding to the CE-mark indications/contra-indications and according to the&#xD;
             current medical guidelines for minimally invasive peripheral interventions.&#xD;
&#xD;
          2. Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable&#xD;
             for stenting (on indication for primary stenting, based on the discretion of the&#xD;
             investigator)&#xD;
&#xD;
          3. Patient presenting a score from 2 to 5 following Rutherford classification&#xD;
&#xD;
          4. Patient is willing to comply with specified follow-up evaluations at the specified&#xD;
             times for the duration of the study&#xD;
&#xD;
          5. Patient is &gt;18 years old&#xD;
&#xD;
          6. Patient (or their legal representative) understands the nature of the procedure and&#xD;
             provides written informed consent, prior to enrolment in the study&#xD;
&#xD;
          7. Patient is eligible for treatment with the BeGraft Peripheral Stent Graft System&#xD;
             (Bentley InnoMed)&#xD;
&#xD;
          8. The target lesion is either a modified TASC-II class A, B, C or D lesion with one of&#xD;
             the listed specifications:&#xD;
&#xD;
               -  Type A lesions&#xD;
&#xD;
                    -  Unilateral or bilateral stenoses of the Common Iliac Artery&#xD;
&#xD;
                    -  Unilateral or bilateral single short (â‰¤3 cm) stenosis of the External Iliac&#xD;
                       Artery&#xD;
&#xD;
               -  Type B lesions&#xD;
&#xD;
                    -  Unilateral Common Iliac Artery occlusion&#xD;
&#xD;
                    -  Single or multiple stenosis totaling 3-10 cm involving the External Iliac&#xD;
                       Artery not extending into the Common Femoral Artery&#xD;
&#xD;
                    -  Unilateral External Iliac Artery occlusion not involving the origins of&#xD;
                       Internal Iliac Artery or Common Iliac Artery&#xD;
&#xD;
               -  Type C lesions&#xD;
&#xD;
                    -  Bilateral Common Iliac Artery occlusions&#xD;
&#xD;
                    -  Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the&#xD;
                       Common Femoral Artery&#xD;
&#xD;
          9. The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or&#xD;
             occlusion which can be passed with standard guidewire manipulation&#xD;
&#xD;
         10. There is angiographic evidence of a patent Common an Deep Femoral Artery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. PTA is technically not possible (not feasible to access the lesion or a defect with&#xD;
             the guidewire or balloon catheter)&#xD;
&#xD;
          2. Presence of an aneurysm immediately adjacent to the site of stent implantation&#xD;
&#xD;
          3. Stenosis distal to the site of stent implantation&#xD;
&#xD;
          4. Lesions in or adjacent to essential collaterals(s)&#xD;
&#xD;
          5. Lesions in locations subject to external compression&#xD;
&#xD;
          6. Heavily calcified lesions resistant to PTA&#xD;
&#xD;
          7. Patients with diffuse distal disease resulting in poor stent outflow&#xD;
&#xD;
          8. Patients with a history of coagulation disorders&#xD;
&#xD;
          9. Patients with aspirin allergy or bleeding complications and patients unable or&#xD;
             unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to&#xD;
             anticoagulant/antiplatelet therapy&#xD;
&#xD;
         10. Fresh thrombus formation&#xD;
&#xD;
         11. Patients with known hypersensitivity to the stent material(L605)&#xD;
&#xD;
         12. The target lesion is either a modified TASC-II class B or D lesion with aortic or&#xD;
             common femoral lesion involvement:&#xD;
&#xD;
               -  Type B lesions&#xD;
&#xD;
                  -Short (â‰¤3 cm) stenosis of infrarenal aorta&#xD;
&#xD;
               -  Type C lesions&#xD;
&#xD;
                    -  Unilateral External Iliac Artery stenosis extending into the Common Femoral&#xD;
                       Artery&#xD;
&#xD;
                    -  Unilateral External Iliac Artery occlusion that involves the origins of the&#xD;
                       Internal Iliac and/or Common Femoral Artery&#xD;
&#xD;
                    -  Heavily calcified unilateral External Iliac Artery occlusion with or without&#xD;
                       involvement of origins of the Internal Iliac and/or Common Femoral Artery&#xD;
&#xD;
               -  Type D lesions&#xD;
&#xD;
                    -  Infra-renal aortoiliac occlusion&#xD;
&#xD;
                    -  Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring&#xD;
                       treatment and not amenable to endograft placement or other lesions requiring&#xD;
                       open aortic or iliac surgery&#xD;
&#xD;
                    -  Diffuse multiple stenoses involving the unilateral Common Iliac, External&#xD;
                       Iliac and Common Femoral Artery&#xD;
&#xD;
                    -  Unilateral occlusions of both Common Iliac and External Iliac Artery&#xD;
&#xD;
                    -  Diffuse disease involving the aorta and both iliac arteries requiring&#xD;
                       treatment&#xD;
&#xD;
                    -  Bilateral occlusions of the External Iliac Artery&#xD;
&#xD;
         13. Previously implanted stent(s) at the same lesion site&#xD;
&#xD;
         14. Reference segment diameter is not suitable for the available stent design&#xD;
&#xD;
         15. Untreatable lesion located at the distal outflow arteries&#xD;
&#xD;
         16. Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation&#xD;
             therapy) as part of the index procedure&#xD;
&#xD;
         17. Patients refusing treatment&#xD;
&#xD;
         18. Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are&#xD;
             contraindicated&#xD;
&#xD;
         19. Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion&#xD;
             site&#xD;
&#xD;
         20. Perforation at the angioplasty site evidenced by extravasation of contrast medium&#xD;
&#xD;
         21. Patients with a history of prior life-threatening contrast medium reaction&#xD;
&#xD;
         22. Patients with uncorrected bleeding disorders&#xD;
&#xD;
         23. Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
         24. Life expectancy of less than twelve months&#xD;
&#xD;
         25. Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
         26. Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
         27. Patient is currently participating in another investigational drug or device study&#xD;
             that has not completed the entire follow up period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen Deloose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flanders Medical Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilig Hart Hospital</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

